Skip to main content
Blood logoLink to Blood
. 2023 Jun 29;141(26):3232. doi: 10.1182/blood.2023019759

Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003.

PMCID: PMC10375266  PMID: 37383001

In Figure 4 on page 3000, the red curves should be blue and the blue curves should be red. In the color key in the upper right corner, a mavorixafor dose of 300 mg should be represented by a blue triangle and a dose of 400 mg by a red square. The corrected Figure 4 is shown below. The error does not affect the conclusions of the study.

Figure 4.

Figure 4.

Dose-dependent hematologic improvement. Mavorixafor produces an initial peak elevation in WBC count, ALC, ANC, and AMC at ∼4 hours postdose. The ALC threshold of 1000 cells per microliter and the ANC threshold of 500 neutrophils per microliter are indicated by dashed lines.

In the HTML version of the article, Figure 4 is erroneously placed before Figure 3.


Articles from Blood are provided here courtesy of The American Society of Hematology

RESOURCES